Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: zurdo who wrote (4022)	7/8/1998 10:58:00 AM
From: Hunter Vann	Read Replies (1) \| Respond to of 9523

Pharmacy Times Ron Gasbarro, PharmD. Drugs to treat erectile dysfunction have been in existence for a while. But they involve intracavernous injections and urethral suppositories. An oral drug is infinitely more palatable than a needle prick to the penis. But Viagra will not have the market to itself much longer--at least two new oral medications and a topical gel are in the works. Snickering and late-night jokes aside, impotence can be the result of a more serious condition, such as diabetes or hypertension. These possibilities must be checked out first. Men with impotence problems should also know that sildenafil is not an aphrodisiac. the rest of the body has to want to have sex. More gently, impotence can also be a sympton of nothing more than agin. A pill, such as sildenafil, that can reverse one of the most disheartening signals that one is "over the hill," will certainly please the human race for some time to come. Sildenafil is a phosphodiesterase (PDE) inhibitor. A PDE is a key enzyme in the regulation of smooth muscle tone. Experimental studies showed that sildenafil specifically palys a key role in the smooth muscle tone of the corpus cavernosum, the two parallel columns of erectile tissue forming the dorsal part of the body of the penis. In an organ bath, strips from human and rabbit corpus cavernosum were precontracted and increasing doses of various PDE inhibitors were added. The results of the study showed that PDE inhibitors dose-dependently relaxed rabbit and human corpus cavernosum strips. Sildenafil was the PDE inhibitor that worked best on human corpus cavernosum.

To: zurdo who wrote (4022)	7/8/1998 11:03:00 AM
From: B.REVERE	Read Replies (1) \| Respond to of 9523

Zurdo, my perception of what is occurring this week is basically this: 1) Those short the stock, or have written puts or sold calls are in a bind right now. Options expire next Friday or at least two days after pfe earnings come out. Do they sit tight with their 110 or 115 options knowing they could be worthless by Wednesday? With pfe going up now on better than expected earnings, they are seeing any paper profits going up in smoke as the minutes tick by. As they close out their positions, the mm's have to buy the stock to cover their position. Anyone who wrote calls will wait until earnings to close out their positions so the downside risk is neglible until earnings are released. 2) The news comung out from Pfiser the last few days have turned positive. Even Ted David on cnbc commented on Monday about how the deaths of men taking Viagra were not proven to be related and that mortality rates within this group were 300 per month. His implication was clear that the media story from the w/s rag was b/s. 3)The positive report from IMS yesterday has opened up the eyes of a lot of analysts who don't do their homework. Brokers who originally felt that pfe was overvalued have had to re-evaluate pfe's projected p/e ratio for next year. Factor in Europe for 1999 and your p/e drops below 40 at this level.To pay 2x the value of a company growing at 22%+ per year, plus knowing that they're pouring money back into r&d every quarter to keep that growth intact is what will drive this stock up. Later, BR